Incyte Corp. closed 14.97% short of its 52-week high of $83.95, which the company reached on November 8th.

“Partnering with Genesis Therapeutics presents a unique opportunity to leverage their AI technologies to accelerate the ...

Incyte (INCY) and Genesis Therapeutics announced that the companies have entered into a strategic collaboration focused on the research, ...

Incyte and Genesis have entered a strategic partnership for the research, discovery and development of new small-molecule ...

Incyte and Genesis Therapeutics have agreed to discover and optimize at least two initial small molecule compounds through Genesis’s AI platform, Genesis Exploration of Molecular Space (GEMS).

This unique rating measures technical performance by showing how a stock's price action over the last 52 weeks measures up ...

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: ...

Incyte stock was one of the biggest decliners on the S&P 500 Monday after the drugmaker's fourth-quarter adjusted profit and ...

(RTTNews) - Thursday, Incyte Corp. (INCY) and Genesis Therapeutics have entered into a strategic partnership focused on the research, discovery, and development of small molecule medicines.

Incyte has a strong track record of revenue growth and a robust pipeline, targeting over 10 high-impact product launches by ...

Incyte is granted exclusive rights for potential clinical development and commercialization of collaboration products. “AI has the potential to redefine how we discover small molecule medicines ...